| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Interim Peo, CFO
1 company
Michael O'Keefe Sullivan last filed a Form 4 in July 2022, as Interim Peo, CFO at OGEN. Michael O'Keefe Sullivan's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 34,255 shares of OGEN. Net of sales, the OGEN filings show accumulation of 20,000 shares.
Michael O'Keefe Sullivan has 10 Form 4 filings on record from March 2015 to July 2022, all as Chief Financial Officer at Oragenics (OGEN), 2015–2022.
The 11 reported transactions were 10 option or other derivative awards and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $7K and no sales.
The only open-market purchase was 20,000 shares of OGEN at an average $0.35 on March 29, 2022, about $7K. Twelve months later OGEN was down 86%.
Shares as reported in the last Form 4 for each company; the most recent is from July 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 29, 2022 | OGEN Oragenics Inc | Interim Peo, CFO | Buy | 20,000 | $0.35 | $6,922.00 | +140.3% | -9.6% | -85.9% |